Europe
October marked the first time this year there was an increase in both the number of biotech and pharma companies trimming their workforces and the number of affected employees when compared to 2025. Still, it’s highly unlikely 2026 layoffs will come close to matching the downsizing seen last year.
The list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.
With backing from three Big Pharma investment arms, British biotech T-Therapeutics is brewing up a clinical launch for its cancer and autoimmune T cell engagers.
As companies invest billions of dollars to reshore manufacturing, 10 biotech and pharma businesses are reportedly trimming staff at manufacturing locations in 2026 or the coming years, with BioNTech having the deepest cuts.
Drug developers increasingly have the option of seeking regulatory approval and commercializing a medicine themselves, rather than accepting an early exit offer. Doing so requires a worldwide strategy.
Since 2025, U.S. biopharma companies have raised $37.2 billion—68% of total worldwide venture capital funding in the industry—with startups in the San Francisco Bay Area and Boston leading the way.
Following the withdrawal of billions of dollars in investments from Boehringer Ingelheim and Eli Lilly, German lawmakers have proposed a clause to the country’s healthcare reforms set to take effect Jan. 1.
The European Commission approved Germany’s financial support after assessing the risks of Sanofi stopping insulin API production at the Frankfurt campus.
At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on Merck and Moderna’s personalized cancer vaccine, Summit and Akeso’s PD-1xVEGF bispecific therapy, and a host of antibody-drug conjugates.
While industry leaders are unsure whether the U.S. or China will prevail, they are largely united in the belief that Europe is lagging behind.
PRESS RELEASES